Non-virological response to a dolutegravir-containing regimen in a patient harbouring a E157Q-mutated virus in the integrase region

被引：22

作者：

Danion, F. ^{[1
,2
,3
]}

Belissa, E. ^{[4
]}

Peytavin, G. ^{[4
,5
]}

Thierry, E. ^{[6
]}

Lanternier, F. ^{[1
,2
,3
]}

Scemla, A. ^{[7
,8
]}

Lortholary, O. ^{[1
,2
,3
]}

Delelis, O. ^{[6
]}

Avettand-Fenoel, V. ^{[9
,10
]}

Duvivier, C. ^{[1
,2
,3
]}

机构：

[1] Hop Necker Enfants Malad, AP HP, Serv Malad Infect & Trop, Ctr Infectiol Necker Pasteur, F-75015 Paris, France

[2] Univ Paris 05, Sorbonne Paris Cite, Paris, France

[3] IHU Imagine, Paris, France

[4] Grp Hosp Xavier Bichat Claude Bernard, AP HP, UF Lab Pharmacotoxicol 301, F-75018 Paris, France

[5] Univ Paris Diderot, Sorbonne Paris Cite, IAME, INSERM,UMR 1137, Paris, France

[6] CNRS, Lab Biol & Pharmacol Appl, UMR8113, Cachan, France

[7] Hop Necker Enfants Malad, AP HP, Serv Nephrol & Transplantat Adulte, F-75015 Paris, France

[8] Univ Paris 05, Sorbonne Paris Cite, RTRS Centaure, Labex Transplantex, Paris, France

[9] Hop Necker Enfants Malad, AP HP, Serv Virol, F-75015 Paris, France

[10] Univ Paris 05, Sorbonne Paris Cite, EA7327, Paris, France

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2015年 / 70卷 / 06期

关键词：

E157Q mutation; dolutegravir resistance; HIV treatment; integrase strand transfer inhibitors; INSTIs; ANTIRETROVIRAL-NAIVE ADULTS; ONCE-DAILY DOLUTEGRAVIR; HIV-1; INFECTION; RALTEGRAVIR;

D O I：

10.1093/jac/dkv012

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

页码：1921 / 1923

页数：3

共 8 条

[1] Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study [J].

Cahn, Pedro ;

Pozniak, Anton L. ;

Mingrone, Horacio ;

Shuldyakov, Andrey ;

Brites, Carlos ;

Andrade-Villanueva, Jaime F. ;

Richmond, Gary ;

Beltran Buendia, Carlos ;

Fourie, Jan ;

Ramgopal, Moti ;

Hagins, Debbie ;

Felizarta, Franco ;

Madruga, Jose ;

Reuter, Tania ;

Newman, Tamara ;

Small, Catherine B. ;

Lombaard, John ;

Grinsztejn, Beatriz ;

Dorey, David ;

Underwood, Mark ;

Griffith, Sandy ;

Min, Sherene .

LANCET, 2013, 382 (9893) :700-708

[2] Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study [J].

Castagna, Antonella ;

Maggiolo, Franco ;

Penco, Giovanni ;

Wright, David ;

Mills, Anthony ;

Grossberg, Robert ;

Molina, Jean-Michel ;

Chas, Julie ;

Durant, Jacques ;

Moreno, Santiago ;

Doroana, Manuela ;

Ait-Khaled, Mounir ;

Huang, Jenny ;

Min, Sherene ;

Song, Ivy ;

Vavro, Cindy ;

Nichols, Garrett ;

Yeo, Jane M. .

JOURNAL OF INFECTIOUS DISEASES, 2014, 210 (03) :354-362

[3] Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study [J].

Clotet, Bonaventura ;

Feinberg, Judith ;

van Lunzen, Jan ;

Khuong-Josses, Marie-Aude ;

Antinori, Andrea ;

Dumitru, Irina ;

Pokrovskiy, Vadim ;

Fehr, Jan ;

Ortiz, Roberto ;

Saag, Michael ;

Harris, Julia ;

Brennan, Clare ;

Fujiwara, Tamio ;

Min, Sherene .

LANCET, 2014, 383 (9936) :2222-2231

[4] Efficient and Specific Internal Cleavage of a Retroviral Palindromic DNA Sequence by Tetrameric HIV-1 Integrase [J].

Delelis, Olivier ;

Parissi, Vincent ;

Leh, Herve ;

Mbemba, Gladys ;

Petit, Caroline ;

Sonigo, Pierre ;

Deprez, Eric ;

Mouscadet, Jean-Francois .

PLOS ONE, 2007, 2 (07)

[5] Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry [J].

Jung, Byung Hwa ;

Rezk, Naser L. ;

Bridges, Arlene S. ;

Corbett, Amanda H. ;

Kashuba, Angela D. M. .

BIOMEDICAL CHROMATOGRAPHY, 2007, 21 (10) :1095-1104

[6] New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors [J].

Malet, Isabelle ;

Arriaga, Laura Gimferrer ;

Artese, Anna ;

Costa, Giosue ;

Parrotta, Lucia ;

Alcaro, Stefano ;

Delelis, Olivier ;

Tmeizeh, Ahmed ;

Katlama, Christine ;

Valantin, Marc-Antoine ;

Ceccherini-Silberstein, Francesca ;

Calvez, Vincent ;

Marcelin, Anne-Genevieve .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (08) :2118-2122

[7] Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial [J].

van Lunzen, Jan ;

Maggiolo, Franco ;

Arribas, Jose R. ;

Rakhmanova, Aza ;

Yeni, Patrick ;

Young, Benjamin ;

Rockstroh, Juergen K. ;

Almond, Steve ;

Song, Ivy ;

Brothers, Cindy ;

Min, Sherene .

LANCET INFECTIOUS DISEASES, 2012, 12 (02) :111-118

[8] Dolutegravir plus Abacavir-Lamivudine for the Treatment of HIV-1 Infection [J].

Walmsley, Sharon L. ;

Antela, Antonio ;

Clumeck, Nathan ;

Duiculescu, Dan ;

Eberhard, Andrea ;

Gutierrez, Felix ;

Hocqueloux, Laurent ;

Maggiolo, Franco ;

Sandkovsky, Uriel ;

Granier, Catherine ;

Pappa, Keith ;

Wynne, Brian ;

Min, Sherene ;

Nichols, Garrett .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (19) :1807-1818

← 1 →